{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:04:50Z","timestamp":1788458690687,"version":"build-2803163510"},"reference-count":155,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio Grande do Sul","doi-asserted-by":"publisher","award":["16\/2551-0000-476-5"],"award-info":[{"award-number":["16\/2551-0000-476-5"]}],"id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003810","name":"Hospital de Cl\u00ednicas de Porto Alegre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003810","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jdiacomp.2020.107774","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T12:51:11Z","timestamp":1603457471000},"page":"107774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease"],"prefix":"10.1016","volume":"35","author":[{"given":"Gustavo Monteiro","family":"Escott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia Guimar\u00e3es","family":"da Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor da Agostim","family":"Cancelier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lica","family":"Dall'Agnol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Pinho","family":"Silveiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2020.107774_bb0005","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1053\/j.ajkd.2018.12.012","article-title":"Chapter 1: incidence, prevalence, patient characteristics, and treatment modalities","volume":"73","author":"United States Renal Data System","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0010","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.kint.2018.07.026","article-title":"Kidney disease in Latin America: current status, challenges, and the role of the ISN in the development of nephrology in the region","volume":"94","author":"Pecoits-Filho","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0015","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00125-013-2966-1","article-title":"Survival in dialysis patients is different between patients with diabetes as primary renal disease and patients with diabetes as a co-morbid condition","volume":"56","author":"Schroijen","year":"2013","journal-title":"Diabetologia."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0203992","article-title":"Cost of chronic kidney disease attributable to diabetes from the perspective of the Brazilian Unified Health System","volume":"13","author":"Goncalves","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0025","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0030","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"United Kingdom Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0035","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0040","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","article-title":"Lipid management in patients with chronic kidney disease","volume":"14","author":"Ferro","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2013.06.020","article-title":"Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis","volume":"63","author":"Hill","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0050","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes\u20132020. Diabetes Care. 2020;43(Supplement 1):S135-S151. doi:https:\/\/doi.org\/10.2337\/dc20-S011","DOI":"10.2337\/dc20-S011"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0055","unstructured":"Kidney Disease: Improving Global, Group O (KDIGO) CW. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(Suppl.):1\u2013150."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11892-018-1044-y","article-title":"Inpatient glycemic management in the setting of renal insufficiency\/failure\/dialysis","volume":"18","author":"Iyengar","year":"2018","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0065","unstructured":"Diabetes SB de. Diretrizes Da Sociedade Brasileira de Diabetes 2019\u20132020. S\u00e3o Paulo; 2020. doi:978-85-93746-13-0."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0070","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.dsx.2018.11.026","article-title":"Chronic kidney disease among US adults with type 2 diabetes and cardiovascular diseases: a national estimate of prevalence by KDIGO 2012 classification","volume":"13","author":"Wang","year":"2019","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0075","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0080","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.2337\/dc11-1282","article-title":"Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation pronouncedly underestimates glomerular filtration rate in type 2 diabetes","volume":"34","author":"Silveiro","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0085","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12882-015-0196-0","article-title":"The Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation does not improve the underestimation of Glomerular Filtration Rate (GFR) in people with diabetes and preserved renal function","volume":"16","author":"MacIsaac","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000450893","article-title":"Glomerular filtration rate in healthy living potential kidney donors: a meta-analysis supporting the construction of the full age spectrum equation","volume":"135","author":"Pottel","year":"2017","journal-title":"Nephron."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0095","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1054\/mehy.1997.0655","article-title":"Important role of the kidney in human carbohydrate metabolism","volume":"52","author":"Stumvoll","year":"1999","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0100","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/ki.1992.414","article-title":"Glucose homeostasis and the kidney","volume":"42","author":"Adrogu\u00e9","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0105","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1093\/ndt\/13.12.2996","article-title":"Glucose production by the human kidney - its importance has been underestimated","volume":"13","author":"Stumvoll","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0110","doi-asserted-by":"crossref","first-page":"F915","DOI":"10.1152\/ajprenal.1998.275.6.F915","article-title":"Effects of physiological hyperinsulinemia on systemic, renal, and hepatic substrate metabolism","volume":"275","author":"Meyer","year":"1998","journal-title":"Am J Physiol Physiol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0115","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1083\/jcb.201802095","article-title":"The cell biology of systemic insulin function","volume":"217","author":"Tokarz","year":"2018","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000439242","article-title":"Use of continuous glucose monitoring in patients with diabetes mellitus on peritoneal dialysis: correlation with glycated hemoglobin and detection of high incidence of unaware hypoglycemia","volume":"41","author":"Qayyum","year":"2016","journal-title":"Blood Purif"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0125","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/eurheartj\/eht332","article-title":"Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial","volume":"34","author":"Mellbin","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0130","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1681\/ASN.2015070756","article-title":"Impaired glucose and insulin homeostasis in moderate-severe CKD","volume":"27","author":"de Boer","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0135","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2125.1999.00092.x","article-title":"The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes","volume":"48","author":"King","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0140","doi-asserted-by":"crossref","unstructured":"Guideline Development Group, Bilo H, Coentrao L, et al. Clinical practice guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL\/min). Nephrol Dial Transplant. 2015;30(suppl 2):ii1-ii142. doi:https:\/\/doi.org\/10.1093\/ndt\/gfv100","DOI":"10.1093\/ndt\/gfv100"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0145","doi-asserted-by":"crossref","unstructured":"American Diabetes Association AD. 6. Glycemic targets: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Supplement 1):S66-S76. doi:https:\/\/doi.org\/10.2337\/dc20-S006","DOI":"10.2337\/dc20-S006"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0150","doi-asserted-by":"crossref","first-page":"20028","DOI":"10.1038\/srep20028","article-title":"Glycated hemoglobin and outcomes in patients with advanced diabetic chronic kidney disease","volume":"6","author":"Kuo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0155","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2337\/dc06-2127","article-title":"A1C and survival in maintenance hemodialysis patients","volume":"30","author":"Kalantar-Zadeh","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0160","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrneph.2015.38","article-title":"Haemodialysis-induced hypoglycaemia and glycaemic disarrays","volume":"11","author":"Abe","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0165","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1038\/s41598-019-39933-5","article-title":"Glycemic control and survival in peritoneal dialysis patients with diabetes: a 2-year nationwide cohort study","volume":"9","author":"Abe","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0170","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1681\/ASN.2010010031","article-title":"Diagnostic application of the A(1c) assay in renal disease","volume":"21","author":"Sharif","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0175","first-page":"178","article-title":"Effect of iron supplementation on glycosylated haemoglobin in non-diabetic individuals with iron deficiency anaemia","volume":"19","author":"Varshney","year":"2018","journal-title":"J Indian Acad Clin Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0180","doi-asserted-by":"crossref","unstructured":"Veeramalla V, Madas S. Correlation of glycated hemoglobin and iron deficiency anemia among diabetic and non diabetic patients. Int J Curr Microbiol Appl Sci. 2017;6(12):2669\u20132675. doi:10.20546\/ijcmas.2017.612.308","DOI":"10.20546\/ijcmas.2017.612.308"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0185","unstructured":"Eltom AE. Impact of iron deficiency anemia on hemoglobin a1c level among Biomedical European of and Pharmaceutical Sciences. 2018;(April)."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0190","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1523-1755.1998.00777.x","article-title":"Carbamylated hemoglobin and carbamylated plasma protein in hemodialyzed patients","volume":"53","author":"Balion","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0195","series-title":"Protein Carbamylation in Chronic Kidney Disease and Dialysis","first-page":"37","author":"Long","year":"2018"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0200","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/00365513.2019.1703213","article-title":"Strong correlation and high comparability of capillary electrophoresis and three different methods for HbA1c measurement in a population without hemoglobinopathy","volume":"80","author":"Sriwimol","year":"2020","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.diabres.2015.01.034","article-title":"Impact of carbamylation on three different methods, HPLC, capillary electrophoresis and TINIA of measuring HbA1c levels in patients with kidney disease","volume":"108","author":"Dolscheid-Pommerich","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0210","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc06-1679","article-title":"Glucose measurement: confounding issues in setting targets for inpatient management","volume":"30","author":"Dungan","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.diabres.2018.03.017","article-title":"Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)","volume":"140","author":"Dozio","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0220","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1440-1797.2011.01517.x","article-title":"Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring","volume":"17","author":"Vos","year":"2012","journal-title":"Nephrology."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0225","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/jcla.21887","article-title":"Falsely elevated glucose concentrations in peritoneal dialysis patients using icodextrin","volume":"30","author":"Dogan","year":"2016","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0230","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3747\/pdi.2008.00285","article-title":"False elevation of blood glucose levels measured by GDH-PQQ-based glucometers occurs during all daily dwells in peritoneal dialysis patients using icodextrin","volume":"30","author":"Tsai","year":"2010","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0235","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/ndt\/17.11.1988","article-title":"Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity","volume":"17","author":"Schoenicke","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0240","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/clinchem\/44.11.2379","article-title":"Positive interference of icodextrin metabolites in some enzymatic glucose methods","volume":"44","author":"Janssen","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0245","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.amjms.2019.07.003","article-title":"Continuous glucose monitoring: review of an innovation in diabetes management","volume":"358","author":"Mian","year":"2019","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0250","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/ndt\/gfp181","article-title":"Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system","volume":"24","author":"Riveline","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0255","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0260","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJM199508313330902","article-title":"Group the MMS. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus","volume":"333","author":"DeFronzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0265","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes","volume":"60","author":"Griffin","year":"2017","journal-title":"Diabetologia."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0270","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/dom.13642","article-title":"Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease","volume":"21","author":"Charytan","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0275","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9343(97)00254-4","article-title":"Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial","volume":"103","author":"Garber","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0280","series-title":"Cochrane Database of Systematic Reviews","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","author":"Salpeter","year":"2010"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0285","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Introduction: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Supplement 1):S1-S2. doi:https:\/\/doi.org\/10.2337\/dc20-Sint","DOI":"10.2337\/dc20-Sint"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0290","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0295","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jama.2019.13206","article-title":"Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function","volume":"322","author":"Roumie","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0300","doi-asserted-by":"crossref","unstructured":"Chu PY, Hackstadt AJ, Chipman J, et al. Hospitalization for lactic acidosis among patients with reduced kidney function treated with metformin or sulfonylureas. Diabetes Care. May 2020:dc192391. doi:https:\/\/doi.org\/10.2337\/dc19-2391","DOI":"10.2337\/figshare.12042783.v2"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0305","unstructured":"U. S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. 2017:1. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm493244.htm. Accessed January 17, 2019."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0310","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1007\/s00330-017-5247-4","article-title":"Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients","volume":"28","author":"van der Molen","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0315","doi-asserted-by":"crossref","unstructured":"Smyth B, Jones C, Saunders J. Prescribing for patients on dialysis. Aust Prescr. 2016;39(1):21\u201324. doi:10.18773\/austprescr.2016.008","DOI":"10.18773\/austprescr.2016.008"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0320","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3747\/pdi.2013.00344","article-title":"Metformin in chronic kidney disease: time for a rethink","volume":"34","author":"Heaf","year":"2014","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0325","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/dme.12515","article-title":"A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure","volume":"31","author":"Adam","year":"2014","journal-title":"Diabet Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0330","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Supplement 1):S37-S47. doi:https:\/\/doi.org\/10.2337\/dc20-S004","DOI":"10.2337\/dc20-S004"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0335","doi-asserted-by":"crossref","unstructured":"Perico N, Ruggenenti P, Remuzzi G. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. Curr Opin Pharmacol. 2017;33(Cvd):34\u201340. doi:https:\/\/doi.org\/10.1016\/j.coph.2017.03.006","DOI":"10.1016\/j.coph.2017.03.006"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0340","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0345","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0350","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0355","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.113.007071","article-title":"Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?","volume":"129","author":"Stanton","year":"2014","journal-title":"Circulation."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0360","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0365","first-page":"149","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"130","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0370","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0385","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.12182","article-title":"Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment","volume":"16","author":"Macha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0390","doi-asserted-by":"crossref","unstructured":"Heerspink HJL, Stef\u00e1nsson B V., Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. September 2020:NEJMoa2024816. doi:https:\/\/doi.org\/10.1056\/NEJMoa2024816","DOI":"10.1056\/NEJMoa2024816"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0395","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0400","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0405","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/dom.12593","article-title":"Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas","volume":"18","author":"Smits","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0410","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0415","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2337\/diacare.21.11.1925","article-title":"Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure","volume":"21","author":"Nauck","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0420","doi-asserted-by":"crossref","first-page":"102","DOI":"10.7326\/M15-1432","article-title":"Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments","volume":"164","author":"Zaccardi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0425","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0430","doi-asserted-by":"crossref","unstructured":"Sorli C, Harashima S-I, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. lancet Diabetes Endocrinol. 2017;5(4):251\u2013260. doi:https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0435","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0440","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/157201","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"2015","author":"Sun","year":"2015","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0450","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1111\/dom.13361","article-title":"Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"20","author":"Andreadis","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0455","doi-asserted-by":"crossref","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (London, England). 2006;368(9548):1696\u20131705. doi:https:\/\/doi.org\/10.1016\/S0140-6736(06)69705-5","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0460","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/s41598-019-38956-2","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis","volume":"9","author":"Pinto","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0465","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0470","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0475","doi-asserted-by":"crossref","unstructured":"Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. lancet Diabetes Endocrinol. 2018;6(11):859\u2013869. doi:https:\/\/doi.org\/10.1016\/S2213-8587(18)30268-7","DOI":"10.1016\/S2213-8587(18)30268-7"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0480","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0485","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0490","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0495","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0500","first-page":"1","article-title":"DPP-4 inhibitors: renoprotective potential and pharmacokinetics in type 2 diabetes mellitus patients with renal impairment","author":"Mikov","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0505","doi-asserted-by":"crossref","unstructured":"Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85(1):9\u201324. doi:https:\/\/doi.org\/10.1016\/S0167-0115(99)00089-0.","DOI":"10.1016\/S0167-0115(99)00089-0"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0510","doi-asserted-by":"crossref","unstructured":"Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012;34(6):1247\u20131258.e22. doi:https:\/\/doi.org\/10.1016\/J.CLINTHERA.2012.04.013","DOI":"10.1016\/j.clinthera.2012.04.013"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0515","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/s41598-017-19055-6","article-title":"Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis","volume":"8","author":"Pinto","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0520","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0525","doi-asserted-by":"crossref","unstructured":"Cheng D, Fei Y, Liu Y, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis. Joles JA, ed. PLoS One. 2014;9(10):e111543. doi:https:\/\/doi.org\/10.1371\/journal.pone.0111543","DOI":"10.1371\/journal.pone.0111543"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0530","series-title":"DPP-4 Inhibitors in Diabetic Patients With Chronic Kidney Disease and End-stage Kidney Disease on Dialysis in Clinical Practice","first-page":"98","author":"Abe","year":"2015"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0535","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0540","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.2337\/diacare.19.11.1194","article-title":"Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group","volume":"19","author":"Rosenstock","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0545","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.20.4.597","article-title":"Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointest","volume":"20","author":"Simonson","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0550","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"United Kingdom Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0555","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00228-003-0592-4","article-title":"Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia","volume":"59","author":"Holstein","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0560","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0272-6386(00)70204-6","article-title":"Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease","volume":"35","author":"Krepinsky","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0565","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/j.1875-9114.1997.tb03103.x","article-title":"Prolonged hypoglycemic crisis associated with glyburide","volume":"17","author":"Sills","year":"1997","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0570","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/diacare.17.9.1026","article-title":"Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans","volume":"17","author":"Rydberg","year":"1994","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0575","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF01218443","article-title":"Pharmacokinetics of glipizide in man: influence of renal insufficiency","volume":"9","author":"Balant","year":"1973","journal-title":"Diabetologia."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0580","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2337\/diabetes.47.3.345","article-title":"Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes","volume":"47","author":"Fuhlendorff","year":"1998","journal-title":"Diabetes."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0585","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2337\/diacare.24.6.983","article-title":"Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes","volume":"24","author":"Hollander","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0590","article-title":"Meglitinide analogues for type 2 diabetes mellitus","volume":"2","author":"Black","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0595","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.0894-0959.2004.17346.x","article-title":"Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease","volume":"17","author":"Snyder","year":"2004","journal-title":"Semin Dial"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0600","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5414\/CNP60090","article-title":"Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure","volume":"60","author":"Inoue","year":"2003","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0605","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2337\/diacare.26.3.886","article-title":"Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function","volume":"26","author":"Hasslacher","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0610","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0615","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2337\/diacare.19.2.151","article-title":"Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy","volume":"19","author":"Iwamoto","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0620","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1172\/JCI119424","article-title":"Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids","volume":"99","author":"Vidal-Puig","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0625","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1056\/NEJM199411033311803","article-title":"Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone","volume":"331","author":"Nolan","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0630","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nm1278","article-title":"Thiazolidinediones expand body fluid volume through PPAR\u03b3 stimulation of ENaC-mediated renal salt absorption","volume":"11","author":"Guan","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0635","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cam4.1354","article-title":"Pioglitazone and bladder cancer risk: a systematic review and meta-analysis","volume":"7","author":"Tang","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0640","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2147\/VHRM.S3119","article-title":"Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes","volume":"4","author":"Laar","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0645","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2337\/diacare.17.6.561","article-title":"Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients: the ESSEN study","volume":"17","author":"Hoffmann","year":"1994","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0650","doi-asserted-by":"crossref","first-page":"928","DOI":"10.7326\/0003-4819-121-12-199412150-00004","article-title":"The efficacy of acarbose in the treatment of patients with non-insulin- dependent diabetes mellitus. A multicenter controlled clinical trial","volume":"121","author":"Chiasson","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0655","doi-asserted-by":"crossref","first-page":"960","DOI":"10.2337\/diacare.22.6.960","article-title":"A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)","volume":"22","author":"Holman","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0660","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/archinte.161.8.1106","article-title":"Predictors of persistence of use of the novel antidiabetic agent acarbose","volume":"161","author":"Catalan","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0665","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0670","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2337\/diacare.28.1.154","article-title":"Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis","volume":"28","author":"van de Laar","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0675","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142020. Diabetes Care. 2020;43(Supplement 1):S98-S110. doi:https:\/\/doi.org\/10.2337\/dc20-S009","DOI":"10.2337\/dc20-S009"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0680","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3949\/ccjm.76a.09054","article-title":"Managing diabetes in hemodialysis patients: observations and recommendations","volume":"76","author":"Shrishrimal","year":"2009","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0685","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2125.2005.02476.x","article-title":"Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment","volume":"60","author":"Holmes","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0690","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/j.jrn.2014.07.011","article-title":"Advantage of insulin glulisine over regular insulin in patients with type 2 diabetes and severe renal insufficiency","volume":"25","author":"Urata","year":"2015","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0695","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/2042018813501188","article-title":"Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?","volume":"4","author":"Kulozik","year":"2013","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0700","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40262-013-0113-2","article-title":"Insulin degludec: pharmacokinetics in patients with renal impairment","volume":"53","author":"Kiss","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0705","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ajcn\/73.1.68","article-title":"Differences in body fat distribution and antioxidant status in Korean men with cardiovascular disease with or without diabetes","volume":"73","author":"Jang","year":"2001","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0710","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.2017.7117","article-title":"Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes","volume":"318","author":"Wysham","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0715","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00592-014-0604-0","article-title":"The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials","volume":"52","author":"D\u017cyga\u0142o","year":"2015","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0720","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13300-014-0076-9","article-title":"Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials","volume":"5","author":"Vora","year":"2014","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0725","doi-asserted-by":"crossref","unstructured":"Quellhorst E. Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration. J Am Soc Nephrol. 2002;13(suppl 1):S92 LP-S96. http:\/\/jasn.asnjournals.org\/content\/13\/suppl_1\/S92.abstract.","DOI":"10.1681\/ASN.V13suppl_1s92"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0730","doi-asserted-by":"crossref","unstructured":"Almalki MH, Altuwaijri MA, Almehthel MS, Sirrs SM, Singh RS. Subcutaneous versus intraperitoneal insulin for patients with diabetes mellitus on continuous ambulatory peritoneal dialysis: meta-analysis of non-randomized clinical trials. Clin Investig Med. 2012;35(3):132. doi:10.25011\/cim.v35i3.16589","DOI":"10.25011\/cim.v35i3.16589"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0735","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1053\/j.ajkd.2004.10.008","article-title":"A comparison of peritonitis rates from the United States Renal Data System database: CAPD versus continuous cycling peritoneal dialysis patients","volume":"45","author":"Oo","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0740","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/089686080502500617","article-title":"Hepatic subcapsular steatosis as a complication associated with intraperitoneal insulin treatment in diabetic peritoneal dialysis patients","volume":"25","author":"Torun","year":"2005","journal-title":"Perit Dial Int J Int Soc Perit Dial"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0745","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1089\/dia.2018.0028","article-title":"Interference assessment of various endogenous and exogenous substances on the performance of the Eversense Long-Term Implantable Continuous Glucose Monitoring System","volume":"20","author":"Lorenz","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0750","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1177\/193229681200600522","article-title":"GlucoMen day continuous glucose monitoring system: a screening for enzymatic and electrochemical interferents","volume":"6","author":"Lucarelli","year":"2012","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0755","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/jdi.12529","article-title":"Serum bilirubin levels are positively associated with glycemic variability in women with type 2 diabetes","volume":"7","author":"Kim","year":"2016","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0760","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/j.1464-5491.2011.03362.x","article-title":"The danger of using inappropriate point-of-care glucose meters in patients on icodextrin dialysis","volume":"28","author":"Perera","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0765","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.7326\/0003-4819-114-12-1020","article-title":"Fingerstick glucose determination in shock","volume":"114","author":"Atkin","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0770","unstructured":"National Kidney Foundation. How to classify CKD. https:\/\/www.kidney.org\/professionals\/explore-your-knowledge\/how-to-classify-ckd. Published 2019. Accessed October 31, 2019."},{"key":"10.1016\/j.jdiacomp.2020.107774_bb0775","doi-asserted-by":"crossref","unstructured":"Rheinberger M, Jung B, Segiet T, et al. Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: the DIAbetes COhoRtE (DIACORE) study. Jandeleit-Dahm K, ed. PLoS One. 2019;14(3):e0213157. doi:https:\/\/doi.org\/10.1371\/journal.pone.0213157","DOI":"10.1371\/journal.pone.0213157"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872720305559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872720305559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:12:02Z","timestamp":1761005522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872720305559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":155,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1056872720305559"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107774","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107774"}}